Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 198 articles:
HTML format
Text format



Single Articles


    April 2017
  1. EMBERTON M
    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.
    PubMed     Text format    


    March 2017
  2. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Text format     Abstract available


  3. KANTHABALAN A, Peters M, Van Vulpen M, McCartan N, et al
    Focal Salvage HIFU in radiorecurrent prostate cancer.
    BJU Int. 2017 Mar 4. doi: 10.1111/bju.13831.
    PubMed     Text format     Abstract available


    February 2017
  4. SPAHN M, Morlacco A, Boxler S, Joniau S, et al
    Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13818.
    PubMed     Text format     Abstract available


  5. VAN LEEUWEN PJ, Hayen A, Thompson JE, Moses D, et al
    A Multiparametric Magnetic Resonance Imaging Based Risk Model to Determine the Risk of Significant Prostate Cancer prior to biopsy.
    BJU Int. 2017 Feb 16. doi: 10.1111/bju.13814.
    PubMed     Text format     Abstract available


  6. HAWKEN SR, Auffenberg GB, Miller DC, Lane BR, et al
    Calculating Life Expectancy to Inform Prostate Cancer Screening and Treatment Decisions.
    BJU Int. 2017 Feb 15. doi: 10.1111/bju.13812.
    PubMed     Text format     Abstract available


  7. VAN DER POEL HG, Wit EM, Acar C, van den Berg NS, et al
    Sentinel node biopsy for prostate cancer: report from a consensus panel meeting.
    BJU Int. 2017 Feb 10. doi: 10.1111/bju.13810.
    PubMed     Text format     Abstract available


  8. MURPHY DG, Hofman M, Lawrentschuk N, Maurer T, et al
    Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
    BJU Int. 2017;119:194-195.
    PubMed     Text format    


    January 2017
  9. MISRA-HEBERT AD, Hu B, Klein EA, Stephenson A, et al
    Prostate Cancer Screening Practices in a Large, Integrated Health System: 2007-2014.
    BJU Int. 2017 Jan 31. doi: 10.1111/bju.13793.
    PubMed     Text format     Abstract available


  10. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Detection of Prostate Cancer Using Magnetic Resonance Imaging/Ultrasonography Fusion Targeted Biopsy in African-American Men.
    BJU Int. 2017 Jan 23. doi: 10.1111/bju.13786.
    PubMed     Text format     Abstract available


  11. PELLEGRINI KL, Sanda MG, Patil D, Long Q, et al
    Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality.
    BJU Int. 2017 Jan 20. doi: 10.1111/bju.13779.
    PubMed     Text format     Abstract available


  12. FAN L, Wang Y, Chenfei C, Pan J, et al
    Chromogranin A and neurone-specific enolase variations during the first three months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Jan 20. doi: 10.1111/bju.13781.
    PubMed     Text format     Abstract available


  13. TRABULSI EJ, Tripathi SK, Gomella L, Solomides C, et al
    Development of a Voided Urine Assay for Detecting Prostate Cancer Noninvasively: A Pilot Study.
    BJU Int. 2017 Jan 11. doi: 10.1111/bju.13775.
    PubMed     Text format     Abstract available


  14. CROUZET S, Blana A, Murat FJ, Pasticier G, et al
    Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.
    BJU Int. 2017 Jan 7. doi: 10.1111/bju.13766.
    PubMed     Text format     Abstract available


  15. POORTHUIS MH, Vernooij RW, van Moorselaar RJ, de Reijke TM, et al
    First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13764.
    PubMed     Text format     Abstract available


  16. TOSOIAN JJ, Druskin SC, Andreas D, Mullane P, et al
    Prostate health index density improves detection of clinically-significant prostate cancer.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13762.
    PubMed     Text format     Abstract available


  17. RESCIGNO P, Rodrigues DN, de Bono JS
    Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.
    BJU Int. 2017;119:3-4.
    PubMed     Text format    


    December 2016
  18. GHADJAR P, Hayoz S, Genitsch V, Zwahlen DR, et al
    Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.
    BJU Int. 2016 Dec 17. doi: 10.1111/bju.13742.
    PubMed     Text format     Abstract available


  19. ALBISINNI S, Artigas C, Aoun F, Biaou I, et al
    Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    BJU Int. 2016 Dec 15. doi: 10.1111/bju.13739.
    PubMed     Text format     Abstract available


  20. DE CASTRO ABREU AL, Fay CE, Park D, Quinn D, et al
    Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for "Node-only" Recurrent Prostate Cancer: Technique and Initial Series.
    BJU Int. 2016 Dec 15. doi: 10.1111/bju.13741.
    PubMed     Text format     Abstract available


  21. WANG LL, Wallis CJ, Sathianathen N, Lawrentschuk N, et al
    ProtecTion from overtreatment - does a randomised trial finally answer the key question in localised prostate cancer?
    BJU Int. 2016 Dec 8. doi: 10.1111/bju.13734.
    PubMed     Text format     Abstract available


    November 2016
  22. GNANAPRAGASAM VJ, Warren AY
    Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualised care without added costs.
    BJU Int. 2016 Nov 22. doi: 10.1111/bju.13721.
    PubMed     Text format     Abstract available


  23. RAUSCHER I, Duwel C, Wirtz M, Schottelius M, et al
    Value of 111 In-PSMA-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.
    BJU Int. 2016 Nov 10. doi: 10.1111/bju.13713.
    PubMed     Text format     Abstract available


  24. HERDEN J, Heidenreich A, Weissbach L
    Risk Stratification - a Tool to predict the Course of Active Surveillance for Localized Prostate Cancer?
    BJU Int. 2016 Nov 10. doi: 10.1111/bju.13715.
    PubMed     Text format     Abstract available


  25. ESCH L, Fahlbusch M, Albers P, Hautzel H, et al
    11C-acetate PET/CT imaging for detection of recurrent disease following radical prostatectomy or radiotherapy in patients with prostate cancer.
    BJU Int. 2016 Nov 8. doi: 10.1111/bju.13706.
    PubMed     Text format     Abstract available


  26. POYET C, Hermanns T
    Prostate cancer risk calculators: still much work ahead.
    BJU Int. 2016;118:670-671.
    PubMed     Text format    


  27. ROCCO B, Boeri L
    Prostate cancer gene 3 assay in the magnetic resonance imaging (MRI)/ultrasonography fusion target biopsy era: a future to believe in.
    BJU Int. 2016;118:672-673.
    PubMed     Text format    


  28. DE LUCA S, Passera R, Cattaneo G, Manfredi M, et al
    High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy af
    BJU Int. 2016;118:723-730.
    PubMed     Text format     Abstract available


    October 2016
  29. GILBERT DC, Duong T, Kynaston HG, Alhasso AA, et al
    Quality of life outcomes from the PATCH trial evaluating LHRH agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
    BJU Int. 2016 Oct 18. doi: 10.1111/bju.13687.
    PubMed     Text format     Abstract available


  30. TILKI D, Preisser F, Tennstedt P, Tober P, et al
    Adjuvant radiation therapy is associated with better oncological outcome compared to salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    BJU Int. 2016 Oct 15. doi: 10.1111/bju.13679.
    PubMed     Text format     Abstract available


  31. LOEB S, Shin SS, Broyles DL, Wei JT, et al
    Prostate Health Index (phi) Improves Multivariable Risk Prediction of Aggressive Prostate Cancer.
    BJU Int. 2016 Oct 15. doi: 10.1111/bju.13676.
    PubMed     Text format     Abstract available


  32. CORFIELD J, Crozier J, Joshua A, Bolton D, et al
    Understanding the role of new systemic agents in the treatment of prostate cancer.
    BJU Int. 2016 Oct 6. doi: 10.1111/bju.13633.
    PubMed     Text format     Abstract available


  33. COONEY KA, Beebe-Dimmer JL
    HOXB13 mutations and prostate cancer risk.
    BJU Int. 2016;118:496-7.
    PubMed     Text format    


  34. MEREDITH G, Wong D, Yaxley J, Coughlin G, et al
    The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    BJU Int. 2016;118 Suppl 3:49-55.
    PubMed     Text format     Abstract available


    September 2016
  35. YAXLEY JW, Lah K, Yaxley JP, Gardiner RA, et al
    Long term outcome of high dose rate (HDR) brachytherapy for intermediate and high risk prostate cancer with a median follow up of 10 years.
    BJU Int. 2016 Sep 15. doi: 10.1111/bju.13659.
    PubMed     Text format     Abstract available


  36. HOFHEINZ RD, Lange C, Ecke T, Kloss S, et al
    Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional QoLiTime study.
    BJU Int. 2016 Sep 12. doi: 10.1111/bju.13658.
    PubMed     Text format     Abstract available


  37. BRANGER N, Maubon T, Traumann M, Thomassin-Piana J, et al
    Is a negative mpMRI really able to rule out significant prostate cancer?: The real life experience.
    BJU Int. 2016 Sep 12. doi: 10.1111/bju.13657.
    PubMed     Text format     Abstract available


  38. LOEB S, Curnyn C, Fagerlin A, Braithwaite RS, et al
    A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.
    BJU Int. 2016 Sep 9. doi: 10.1111/bju.13651.
    PubMed     Text format     Abstract available


  39. MARTORANA E, Pirola GM, Scialpi M, Micali S, et al
    Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with PIRADS score.
    BJU Int. 2016 Sep 8. doi: 10.1111/bju.13649.
    PubMed     Text format     Abstract available


  40. EGEVAD L, Samaratunga H, Srigley JR, Delahunt B, et al
    Consensus guidelines for reporting prostate cancer Gleason Grade.
    BJU Int. 2016;118:E1-2.
    PubMed     Text format    


  41. JOHNSON MH
    Tailored prostate cancer survivorship: one size does not fit all.
    BJU Int. 2016;118:343-4.
    PubMed     Text format    


  42. EHDAIE B
    Active surveillance for prostate cancer: is it too active?
    BJU Int. 2016;118:343.
    PubMed     Text format    


    August 2016
  43. WILLIAMS SB, Chamie K, Duan Z, Hoffman KE, et al
    Risk of Hospitalization Following Primary Treatment for Prostate Cancer.
    BJU Int. 2016 Aug 25. doi: 10.1111/bju.13647.
    PubMed     Text format     Abstract available


  44. MCDANIEL AS, Ferraldeschi R, Krupa R, Landers M, et al
    Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    BJU Int. 2016 Aug 18. doi: 10.1111/bju.13631.
    PubMed     Text format     Abstract available


  45. BECKMANN KR, O'Callaghan ME, Ruseckaite R, Kinnear N, et al
    Prostate cancer outcomes for men who present with symptoms at diagnosis.
    BJU Int. 2016 Aug 4. doi: 10.1111/bju.13622.
    PubMed     Text format     Abstract available


  46. HANSEN NL, Barrett T, Koo B, Doble A, et al
    The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
    BJU Int. 2016 Aug 4. doi: 10.1111/bju.13619.
    PubMed     Text format     Abstract available


  47. PATEL VR, Palayapalayam Ganapathi H
    Management dilemmas in low-risk prostate cancer.
    BJU Int. 2016;118:180-1.
    PubMed     Text format    


  48. FLAMIATOS JF, Beer TM, Graff JN, Eilers KM, et al
    COX-2 Inhibition for Prostate Cancer Chemoprevention: Double-Blind Randomized Study of Pre-Prostatectomy Celecoxib or Placebo.
    BJU Int. 2016 Aug 1. doi: 10.1111/bju.13612.
    PubMed     Text format     Abstract available



  49. Abstracts of the 17th Asia-Pacific Prostate Cancer Conference 2016, Australia, 31 August-3 September 2016.
    BJU Int. 2016;118 Suppl 1:6-42.
    PubMed     Text format    



  50. Welcome for APCC BJUi Supplement Embracing a precision approach to prostate cancer.
    BJU Int. 2016;118 Suppl 1:5.
    PubMed     Text format    


    July 2016
  51. MAYER EN, Tward JD, Bassett M, Lenherr SM, et al
    Management of Radiation Therapy Oncology Group (RTOG) grade 4 urinary adverse events (UAEs) from radiotherapy for prostate cancer.
    BJU Int. 2016 Jul 28. doi: 10.1111/bju.13607.
    PubMed     Text format     Abstract available


  52. EMERY JD, Jefford M, King M, Hayne D, et al
    The ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer.
    BJU Int. 2016 Jul 19. doi: 10.1111/bju.13593.
    PubMed     Text format     Abstract available


  53. HEGEMANN M, Stenzl A, Bedke J, Chi KN, et al
    Liquid biopsy: ready to guide therapy in advanced prostate cancer?
    BJU Int. 2016 Jul 19. doi: 10.1111/bju.13586.
    PubMed     Text format     Abstract available


  54. LANE JA, Metcalfe C, Young GJ, Peters TJ, et al
    Patient-reported outcomes in the ProtecT randomised trial of clinically localised prostate cancer treatments: design and baseline urinary, bowel and sexual function and quality of life.
    BJU Int. 2016 Jul 14. doi: 10.1111/bju.13582.
    PubMed     Text format     Abstract available


  55. ZHANG BY, Riska SM, Mahoney DW, Costello BA, et al
    Germline Genetic Variation in JAK2 as a Prognostic Marker in Castration Resistant Prostate Cancer.
    BJU Int. 2016 Jul 13. doi: 10.1111/bju.13584.
    PubMed     Text format     Abstract available


  56. DEBRUYNE FM, Behre HM, Roehrborn CG, Maggi M, et al
    Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: Prostate health outcomes in the Registry of Hypogonadism in Men (RHYME).
    BJU Int. 2016 Jul 13. doi: 10.1111/bju.13578.
    PubMed     Text format     Abstract available


  57. LEYH-BANNURAH SR, Abou-Haidar H, Dell'Oglio P, Schiffmann J, et al
    Primary Gleason Pattern Upgrading in contemporary D'Amico low-risk prostate cancer patients: Implications for future biomarkers and imaging modalities.
    BJU Int. 2016 Jul 1. doi: 10.1111/bju.13570.
    PubMed     Text format     Abstract available


    June 2016
  58. ANDRONIS L, Goranitis I, Pirrie S, Pope A, et al
    Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
    BJU Int. 2016 Jun 3. doi: 10.1111/bju.13549.
    PubMed     Text format     Abstract available


  59. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Consensus guidelines for reporting prostate cancer Gleason Grade.
    BJU Int. 2016;117:849.
    PubMed     Text format    


    May 2016
  60. DE CARVALHO TM, Heijnsdijk EA, de Koning HJ
    Estimating the risks and benefits of Active Surveillance protocols for Prostate Cancer: A microsimulation study.
    BJU Int. 2016 May 25. doi: 10.1111/bju.13542.
    PubMed     Text format     Abstract available


  61. WINTER A, Sirri E, Jansen L, Wawroschek F, et al
    Comparison of prostate cancer survival in Germany and the United States: Can differences be attributed to differences in stage distributions?
    BJU Int. 2016 May 21. doi: 10.1111/bju.13537.
    PubMed     Text format     Abstract available


  62. VAN LEEUWEN PJ, Emmett L, Ho B, Delprado W, et al
    Prospective Evaluation of 68Gallium-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Prostate Cancer.
    BJU Int. 2016 May 21. doi: 10.1111/bju.13540.
    PubMed     Text format     Abstract available


  63. DURAND M, Jain M, Robinson B, Aronowitz E, et al
    Magnetic Resonance Microscopy May Enable Distinction Between Normal Histomorphological Features and Prostate Cancer in the Resected Prostate Gland.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13523.
    PubMed     Text format     Abstract available


  64. RAISON N, Elhage O, Dasgupta P
    Getting Personal with Prostate Cancer: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13522.
    PubMed     Text format     Abstract available


  65. PATEL U, Dasgupta P, Challacombe B, Cahill D, et al
    Pre-biopsy 3T MRI and targeted biopsy of the index prostate cancer - correlation with robot assisted radical prostatectomy.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13525.
    PubMed     Text format     Abstract available


  66. GORIN MA, Pomper MG, Rowe SP
    PSMA-targeted imaging of prostate cancer: the best is yet to come.
    BJU Int. 2016;117:715-6.
    PubMed     Text format    


  67. CUSSANS A, Somani BK, Basarab A, Dudderidge TJ, et al
    The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review.
    BJU Int. 2016;117:725-31.
    PubMed     Text format     Abstract available


    April 2016
  68. FODOR A, Berardi G, Fiorino C, Picchio M, et al
    Toxicity and efficacy of salvage 11C-Choline PET/CT-guided radiation therapy in patients with prostate cancer lymph nodal recurrence.
    BJU Int. 2016 Apr 22. doi: 10.1111/bju.13510.
    PubMed     Text format     Abstract available


  69. BOKHORST LP, Zappa M, Carlsson SV, Kwiatkowski M, et al
    Correlation between stage shift and differences in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2016 Apr 22. doi: 10.1111/bju.13505.
    PubMed     Text format     Abstract available


  70. WHITING PF, Moore TH, Jameson CM, Davies P, et al
    Symptomatic and quality of life outcomes following treatment for clinically localized prostate cancer: a systematic review.
    BJU Int. 2016 Apr 18. doi: 10.1111/bju.13499.
    PubMed     Text format     Abstract available


  71. SELKIRK CG, Helfand BT
    To PSA or not to PSA? Still a question for men with a family history of prostate cancer.
    BJU Int. 2016;117:545.
    PubMed     Text format    


  72. ERNSTMANN N, Weissbach L, Herden J, Winter N, et al
    Patient-physician-communication and health related quality of life of localized prostate cancer patients undergoing radical prostatectomy - a longitudinal multilevel analysis.
    BJU Int. 2016 Apr 1. doi: 10.1111/bju.13495.
    PubMed     Text format     Abstract available


  73. WONG LM, Tang V, Peters J, Costello A, et al
    Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
    BJU Int. 2016;117 Suppl 4:82-7.
    PubMed     Text format     Abstract available


  74. DELAHUNT B, Egevad L, Grignon DJ, Srigley JR, et al
    Prostate cancer grading: recent developments and future directions.
    BJU Int. 2016;117 Suppl 4:7-8.
    PubMed     Text format    


  75. LAWRENTSCHUK N
    PSA testing and early management of test-detected prostate cancer- consensus at last.
    BJU Int. 2016;117 Suppl 4:5-6.
    PubMed     Text format    


  76. RASTINEHAD AR, Durand M
    A comparison of magnetic resonance imaging and ultrasonography (MRI/US)-fusion guided prostate biopsy devices: too many uncontrolled variables.
    BJU Int. 2016;117:548-9.
    PubMed     Text format    


  77. CULIG Z
    New possibilities for urinary molecular diagnostics.
    BJU Int. 2016;117:547-8.
    PubMed     Text format    


  78. SUN M, Trinh QD
    A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities.
    BJU Int. 2016;117:551-2.
    PubMed     Text format    


  79. SELES M, Gutschi T, Mayrhofer K, Fischereder K, et al
    Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate.
    BJU Int. 2016;117:592-7.
    PubMed     Text format     Abstract available


  80. KAMRAVA M, Hegde JV, Abgaryan N, Chang E, et al
    Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?
    BJU Int. 2016;117:584-91.
    PubMed     Text format     Abstract available


  81. ANG M, Rajcic B, Foreman D, Moretti K, et al
    Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    BJU Int. 2016;117 Suppl 4:68-75.
    PubMed     Text format     Abstract available


  82. CHEN EC, Papa N, Lawrentschuk N, Bolton D, et al
    Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery--a single center experience.
    BJU Int. 2016;117 Suppl 4:50-3.
    PubMed     Text format     Abstract available


    March 2016
  83. HAGGSTROM C, Stattin P, Stocks T, Garmo H, et al
    Interpretation of conventional survival analysis and competing risk analysis: An example of hypertension and prostate cancer.
    BJU Int. 2016 Mar 31. doi: 10.1111/bju.13494.
    PubMed     Text format     Abstract available


  84. HECK MM, Thaler MA, Schmid SC, Seitz AK, et al
    Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in metastatic castration-resistant prostate cancer patients under abiraterone therapy.
    BJU Int. 2016 Mar 31. doi: 10.1111/bju.13493.
    PubMed     Text format     Abstract available


  85. SPRATT DE, Cole AI, Palapattu GS, Weizer AZ, et al
    Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.
    BJU Int. 2016 Mar 24. doi: 10.1111/bju.13488.
    PubMed     Text format     Abstract available


  86. SHIOTA M, Yokomizo A, Takeuchi A, Kiyoshima K, et al
    Steroid co-introduction with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
    BJU Int. 2016 Mar 17. doi: 10.1111/bju.13483.
    PubMed     Text format     Abstract available


  87. SHORE ND, Chu F, Moul J, Saltzstein D, et al
    ATRIGEL polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate levels of testosterone in four open label studies in advanced prostate cancer patients.
    BJU Int. 2016 Mar 17. doi: 10.1111/bju.13482.
    PubMed     Text format     Abstract available


  88. BORKOWETZ A, Platzek I, Toma M, Renner T, et al
    Direct comparison of multiparametric MRI and final histopathology in patients with proven prostate cancer in MRI/Ultrasound-fusion biopsy.
    BJU Int. 2016 Mar 2. doi: 10.1111/bju.13461.
    PubMed     Text format     Abstract available


  89. COLE AP, Leow JJ, Trinh QD
    New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (COX) blockers in erectile dysfunction.
    BJU Int. 2016;117:385-6.
    PubMed     Text format    


  90. LUNDON DJ
    Prostate cancer risk prediction and the persistence of uncertainty.
    BJU Int. 2016;117:382.
    PubMed     Text format    


  91. ROOBOL MJ
    Where we are with screening and risk prediction for prostate cancer in 2016.
    BJU Int. 2016;117:381.
    PubMed     Text format    


  92. LOEB S
    Prostate biopsy decisions: one-size-fits-all approach with total PSA is out and a multivariable approach with the Prostate Health Index is in.
    BJU Int. 2016;117:383.
    PubMed     Text format    


  93. NAMIKI S, Mitsuzuka K, Kaiho Y, Yamada S, et al
    Serum luteinizing hormone concentration is significantly associated with recovery of urinary function after radical prostatectomy.
    BJU Int. 2016;117:450-5.
    PubMed     Text format     Abstract available


  94. MAI Z, Yan W, Zhou Y, Zhou Z, et al
    Transperineal template-guided prostate biopsy: 10 years of experience.
    BJU Int. 2016;117:424-9.
    PubMed     Text format     Abstract available


    February 2016
  95. DE LA TAILLE A, Martinez-Pineiro L, Cabri P, Houchard A, et al
    Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen deprivation therapy.
    BJU Int. 2016 Feb 25. doi: 10.1111/bju.13455.
    PubMed     Text format     Abstract available


  96. VAN DIE MD, Bone KM, Emery J, Williams SG, et al
    Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.
    BJU Int. 2016 Feb 22. doi: 10.1111/bju.13361.
    PubMed     Text format     Abstract available


  97. GOODALL PP, Little J, Robinson E, Trimble I, et al
    Initial experience of an algorithm-based protocol for the community follow-up of men with prostate cancer.
    BJU Int. 2016 Feb 15. doi: 10.1111/bju.13446.
    PubMed     Text format     Abstract available


  98. EVANS SM, Nag N, Roder D, Brooks A, et al
    Development of an International Prostate Cancer Outcomes Registry.
    BJU Int. 2016 Feb 15. doi: 10.1111/bju.13258.
    PubMed     Text format     Abstract available


  99. CARLSSON S, Jaderling F, Wallerstedt A, Nyberg T, et al
    Oncologic and functional outcomes one year after radical prostatectomy for very low risk prostate cancer. Results from the prospective LAPPRO trial.
    BJU Int. 2016 Feb 11. doi: 10.1111/bju.13444.
    PubMed     Text format     Abstract available


  100. JEFFERIES ER, Bahl A, Hounsome L, Eylert MF, et al
    Admissions to hospital due to fracture in England in prostate cancer patients treated with Androgen Deprivation Therapy (ADT) - do we have to worry about the hormones?
    BJU Int. 2016 Feb 6. doi: 10.1111/bju.13441.
    PubMed     Text format     Abstract available


  101. FOLEY RW, Maweni RM, Gorman L, Murphy K, et al
    The ERSPC Risk Calculators Significantly Outperform The PCPT 2.0 In The Prediction Of Prostate Cancer; A Multi-Institutional Study.
    BJU Int. 2016 Feb 2. doi: 10.1111/bju.13437.
    PubMed     Text format     Abstract available


  102. YAP SA
    Should we worry about positive surgical margins in prostate cancer?
    BJU Int. 2016;117:207-8.
    PubMed     Text format    


    January 2016
  103. RUDMAN SM, Gray KP, Batista JL, Pitt MJ, et al
    Risk of prostate cancer specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.
    BJU Int. 2016 Jan 25. doi: 10.1111/bju.13428.
    PubMed     Text format     Abstract available


  104. MADAN RA, Karzai FH, Ning YM, Adesunloye BA, et al
    Phase II Trial of Docetaxel, Bevacizumab, Lenalidomide, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13412.
    PubMed     Text format     Abstract available


  105. BOYLE P, Koechlin A, Bota M, d'Onofrio A, et al
    Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13417.
    PubMed     Text format     Abstract available


  106. STOREBJERG TM, Hoyer S, Kirkegaard P, Bro F, et al
    Prevalence of the HOXB13 G84E mutation in Danish men treated by radical prostatectomy and correlations with prostate cancer risk and aggressiveness.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13416.
    PubMed     Text format     Abstract available


  107. BOKHORST LP, Lepisto I, Kakehi Y, Bangma CH, et al
    Complications after prostate biopsies in men on active surveillance and its effect on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
    BJU Int. 2016 Jan 14. doi: 10.1111/bju.13410.
    PubMed     Text format     Abstract available


  108. FREEDLAND SJ, Howard LE, Hanyok BT, Kadiyala VK, et al
    Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.
    BJU Int. 2016 Jan 13. doi: 10.1111/bju.13405.
    PubMed     Text format     Abstract available


  109. VELTRI RW
    Serum marker %[-2]proPSA and the Prostate Health Index improve diagnostic accuracy for clinically relevant prostate cancer.
    BJU Int. 2016;117:12-13.
    PubMed     Text format    


  110. EMBERTON M
    Doubling our precision of risk stratification in early prostate cancer: too good to be true?
    BJU Int. 2016;117:8-9.
    PubMed     Text format    


  111. CHANDRASEKAR T, Evans CP
    Salvage radical prostatectomy: a few good men.
    BJU Int. 2016;117:9-10.
    PubMed     Text format    


  112. WILLIAMS SB, Bozkurt Y, Achim M, Achim G, et al
    Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency.
    BJU Int. 2016;117:192-8.
    PubMed     Text format     Abstract available


    December 2015
  113. GILSON C, Sydes MR, Chowdhury S
    Will chemotherapy change the management of prostate cancer?
    BJU Int. 2015 Dec 22. doi: 10.1111/bju.13400.
    PubMed     Text format     Abstract available


  114. VAN LEEUWEN PJ, Stricker P, Hruby G, Kneebone A, et al
    68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    BJU Int. 2015 Dec 18. doi: 10.1111/bju.13397.
    PubMed     Text format     Abstract available


  115. PAL SK, Sonpavde G
    Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
    BJU Int. 2015;116:839-40.
    PubMed     Text format    


  116. EMBERTON M
    Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care?
    BJU Int. 2015;116:837-9.
    PubMed     Text format    


  117. HANSKE J, Meyer CP, Trinh QD
    How can we improve surgical outcomes?
    BJU Int. 2015;116:835-6.
    PubMed     Text format    


  118. ALBERTSEN PC
    Surgery is possible: now let's prove its superior efficacy!
    BJU Int. 2015;116:834-5.
    PubMed     Text format    


  119. BAHL A, Masson S, Malik Z, Birtle AJ, et al
    Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
    BJU Int. 2015;116:880-7.
    PubMed     Text format     Abstract available


  120. NOVARA G, Ficarra V, Zattoni F, Fedeli U, et al
    Recourse to radical prostatectomy and associated short-term outcomes in Italy: a country-wide study over the last decade.
    BJU Int. 2015;116:862-7.
    PubMed     Text format     Abstract available


  121. MONTORSI F, Gandaglia G, Briganti A
    Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?
    BJU Int. 2015;116:845-6.
    PubMed     Text format    


  122. SCHMID M, Ghani KR, Choueiri TK, Sood A, et al
    An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer.
    BJU Int. 2015;116:911-9.
    PubMed     Text format     Abstract available


  123. TULIAO PH, Koo KC, Komninos C, Chang CH, et al
    Number of positive preoperative biopsy cores is a predictor of positive surgical margins (PSM) in small prostates after robot-assisted radical prostatectomy (RARP).
    BJU Int. 2015;116:897-904.
    PubMed     Text format     Abstract available


  124. MOORE CM, Azzouzi AR, Barret E, Villers A, et al
    Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    BJU Int. 2015;116:888-96.
    PubMed     Text format     Abstract available


    November 2015
  125. ONG WL, Evans SM, Spelman T, Kearns PA, et al
    Comparison of oncological and health related quality of life (HRQOL) outcomes between open (ORP) and robotic-assisted radical prostatectomy (RARP) for localized prostate cancer - findings from the population-based Victorian Prostate Cancer Registry (P
    BJU Int. 2015 Nov 17. doi: 10.1111/bju.13380.
    PubMed     Text format     Abstract available


  126. ROLLE L, Falcone M, Ceruti C, Timpano M, et al
    A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the "Sliding Technique" for end-stage Peyronie's disease with severe shortening of the penis and erectile dysfunction.
    BJU Int. 2015 Nov 11. doi: 10.1111/bju.13370.
    PubMed     Text format     Abstract available


  127. SPAHN M
    More nomograms or better lymph node dissection - what do we need in prostate cancer?
    BJU Int. 2015;116:676-7.
    PubMed     Text format    


  128. ALBERTSEN PC
    Does a positive margin always mandate adjuvant radiotherapy?
    BJU Int. 2015;116:677-8.
    PubMed     Text format    


  129. LOEB S, Ribal MJ
    Controversies in management of high-risk prostate and bladder cancer.
    BJU Int. 2015;116:675.
    PubMed     Text format    


  130. KUMAR A, Samavedi S, Bates AS, Coelho RF, et al
    Continence outcomes of robot-assisted radical prostatectomy in patients with adverse urinary continence risk factors.
    BJU Int. 2015;116:764-70.
    PubMed     Text format     Abstract available


  131. HSU CC, Paciorek AT, Cooperberg MR, Roach M 3rd, et al
    Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    BJU Int. 2015;116:713-20.
    PubMed     Text format     Abstract available


  132. MELVIN JC, Garmo H, Daniel R, Shanmugalingam T, et al
    An investigation into the relationship between statins and cancer using population-based data.
    BJU Int. 2015;116:681-3.
    PubMed     Text format    


    October 2015
  133. MOLLER MH, Kristiansen IS, Beisland C, Rorvik J, et al
    Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: A population-based study.
    BJU Int. 2015 Oct 24. doi: 10.1111/bju.13364.
    PubMed     Text format     Abstract available


  134. O'FARRELL S, Sandstrom K, Garmo H, Stattin P, et al
    Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation.
    BJU Int. 2015 Oct 24. doi: 10.1111/bju.13360.
    PubMed     Text format     Abstract available


  135. PAYNE H, Davda R, Jones R, Crabb S, et al
    Advances in Advanced Prostate Cancer - The Continuing Journey.
    BJU Int. 2015 Oct 11. doi: 10.1111/bju.13350.
    PubMed     Text format     Abstract available


  136. FAY AP, Bellmunt J
    Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?
    BJU Int. 2015;116:500-1.
    PubMed     Text format    


  137. MATSUSHITA K, Kent MT, Vickers AJ, von Bodman C, et al
    Preoperative predictive model of recovery of urinary continence after radical prostatectomy.
    BJU Int. 2015;116:577-83.
    PubMed     Text format     Abstract available


  138. SCOTT S, Samaratunga H, Chabert C, Breckenridge M, et al
    Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
    BJU Int. 2015;116 Suppl 3:26-30.
    PubMed     Text format     Abstract available


  139. MCCOMBIE SP, Hawks C, Emery JD, Hayne D, et al
    A 'One Stop' Prostate Clinic for rural and remote men: a report on the first 200 patients.
    BJU Int. 2015;116 Suppl 3:11-7.
    PubMed     Text format     Abstract available


  140. ROTH H, Millar JL, Cheng AC, Byrne A, et al
    The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy-related infection over 5 years.
    BJU Int. 2015;116 Suppl 3:49-53.
    PubMed     Text format     Abstract available


  141. SUNDI D, Han M
    Brachytherapy for prostate cancer: feasible but oncological equivalence unproven.
    BJU Int. 2015;116 Suppl 3:89-91.
    PubMed     Text format    


    September 2015
  142. BERNAT JK, Wittmann DA, Hawley ST, Hamstra DA, et al
    Symptom burden and information needs in prostate cancer survivors: A case for tailored long-term survivorship care.
    BJU Int. 2015 Sep 21. doi: 10.1111/bju.13329.
    PubMed     Text format     Abstract available


  143. EHDAIE B, Poon BY, Sjoberg DD, Recabal P, et al
    Variation of Serum Prostate-Specific Antigen in Men with Prostate Cancer Managed with Active Surveillance.
    BJU Int. 2015 Sep 19. doi: 10.1111/bju.13328.
    PubMed     Text format     Abstract available


  144. CASH H, Gunzel K, Maxeiner A, Stephan C, et al
    Men with a negative real-time MRI/ultrasound-fusion guided targeted biopsy but prostate cancer detection on TRUS-guided random biopsy - what are the reasons for targeted biopsy failure?
    BJU Int. 2015 Sep 19. doi: 10.1111/bju.13327.
    PubMed     Text format     Abstract available


  145. REEVES F, Costello AJ
    Is there a place for cytoreduction in metastatic prostate cancer?
    BJU Int. 2015 Sep 19. doi: 10.1111/bju.13323.
    PubMed     Text format     Abstract available


  146. PORPIGLIA F, Cantiello F, De Luca S, Manfredi M, et al
    In parallel comparative evaluation between multiparametric mri, pca3 and phi in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
    BJU Int. 2015 Sep 9. doi: 10.1111/bju.13318.
    PubMed     Text format     Abstract available


  147. MOUL JW
    Hot topic of cancer survivorship and the 'seven deadly sins'.
    BJU Int. 2015;116:310-1.
    PubMed     Text format    


  148. DAVIS JW
    Clever surgeons and challenging study endpoints.
    BJU Int. 2015;116:309.
    PubMed     Text format    


  149. GUPTA R, O'Connell R, Haynes AM, Stricker PD, et al
    Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?
    BJU Int. 2015;116:343-50.
    PubMed     Text format     Abstract available


  150. DURAND M, Jain M, Aggarwal A, Robinson BD, et al
    Real-time in vivo periprostatic nerve tracking using multiphoton microscopy in a rat survival surgery model: a promising pre-clinical study for enhanced nerve-sparing surgery.
    BJU Int. 2015;116:478-86.
    PubMed     Text format     Abstract available


    August 2015
  151. POYET C, Nieboer D, Bhindi B, Kulkarni GS, et al
    Prostate cancer risk prediction using the novel versions of the ERSPC and PCPT risk calculators: Independent validation and comparison in a contemporary European cohort.
    BJU Int. 2015 Aug 31. doi: 10.1111/bju.13314.
    PubMed     Text format     Abstract available


  152. RANDAZZO M, Muller A, Carlsson S, Eberli D, et al
    A Positive Family History as risk factor for Prostate Cancer in a Population-based Study with organized PSA-Screening: Results of the Swiss ERSPC (Aarau).
    BJU Int. 2015 Aug 31. doi: 10.1111/bju.13310.
    PubMed     Text format     Abstract available


  153. HERDEN J, Wille S, Weissbach L
    Active Surveillance in localized prostate cancer: Comparison of incidental tumors (T1a/b) and tumors diagnosed by core needle biopsy (T1c/T2a). Results from the HAROW Study.
    BJU Int. 2015 Aug 31. doi: 10.1111/bju.13308.
    PubMed     Text format     Abstract available


  154. MORGIA G, Russo GI, Tubaro A, Bortolus R, et al
    Patterns of prescription and adherence to EAU Guidelines of androgen deprivation therapy in prostate cancer: an Italian multicenter cross-sectional analysis from the CHOsIng treatment for prostate canCEr (CHOICE) study.
    BJU Int. 2015 Aug 31. doi: 10.1111/bju.13307.
    PubMed     Text format     Abstract available


  155. VALERIO M, Anele C, Charman SC, van der Meulen J, et al
    Transperineal template prostate mapping biopsies: an evaluation of different protocols in detection of clinically significant prostate cancer.
    BJU Int. 2015 Aug 30. doi: 10.1111/bju.13306.
    PubMed     Text format     Abstract available


  156. ONG WL, Manohar P, Millar J, Royce P, et al
    Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre.
    BJU Int. 2015 Aug 28. doi: 10.1111/bju.13097.
    PubMed     Text format     Abstract available


  157. MOREIRA DM, Gershman B, Rangel LJ, Boorjian SA, et al
    Evaluation of pT0 prostate cancer in radical prostatectomy patients.
    BJU Int. 2015 Aug 25. doi: 10.1111/bju.13266.
    PubMed     Text format     Abstract available


  158. PATEL DP, Schenk JM, Darke A, Myers JB, et al
    Non-steroidal Anti-inflammatory Drug use Not Associated with Erectile Dysfunction Risk: Results from the Prostate Cancer Prevention Trial.
    BJU Int. 2015 Aug 25. doi: 10.1111/bju.13264.
    PubMed     Text format     Abstract available


  159. DALELA D, Krishna N, Okwara J, Preston MA, et al
    Suicide and accidental deaths among patients with loco-regional prostate cancer.
    BJU Int. 2015 Aug 25. doi: 10.1111/bju.13257.
    PubMed     Text format     Abstract available


  160. CHAO MW, Grimm P, Yaxley J, Jagavkar R, et al
    Brachytherapy- State Of The Art Radiotherapy In Prostate Cancer.
    BJU Int. 2015 Aug 11. doi: 10.1111/bju.13252.
    PubMed     Text format     Abstract available


  161. GAYET M, van der Aa A, Beerlage HP, Schrier BP, et al
    The value of MR/US fusion prostate biopsy platforms in prostate cancer detection, a systematic review.
    BJU Int. 2015 Aug 3. doi: 10.1111/bju.13247.
    PubMed     Text format     Abstract available



  162. Abstracts of the 2nd Prostate Cancer World Congress, Australia, 17-21 August 2015.
    BJU Int. 2015;116 Suppl 1:2-57.
    PubMed     Text format    



  163. Welcome for PCWC BJUI supplement A global perspective from the Prostate Cancer World Congress.
    BJU Int. 2015;116 Suppl 1:1.
    PubMed     Text format    


  164. MURALIDHAR V, Mahal BA, Nezolosky MD, Beard CJ, et al
    Association between very small tumor size and increased cancer-specific mortality following radical prostatectomy in node-positive prostate cancer.
    BJU Int. 2015 Aug 1. doi: 10.1111/bju.13248.
    PubMed     Text format     Abstract available


  165. STOLZENBURG JU, Graefen M, Kriegel C, Michl U, et al
    Effect of surgical approach on erectile function recovery following bilateral nerve-sparing radical prostatectomy: an evaluation utilising data from a randomised, double-blind, double-dummy multicentre trial of tadalafil vs placebo.
    BJU Int. 2015;116:241-51.
    PubMed     Text format     Abstract available


  166. KWELDAM CF, Wildhagen MF, Bangma CH, van Leenders GJ, et al
    Disease-specific death and metastasis do not occur in patients with Gleason score </=6 at radical prostatectomy.
    BJU Int. 2015;116:230-5.
    PubMed     Text format     Abstract available


    July 2015
  167. O'NEIL LM, Walsh S, Cohen RJ, Lee S, et al
    Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.
    BJU Int. 2015 Jul 27. doi: 10.1111/bju.13173.
    PubMed     Text format     Abstract available


  168. MAHAL BA, Muralidhar V, Chen YW, Choueiri TK, et al
    Gleason 5 + 3 = 8 Prostate Cancer: Much More like Gleason 9?
    BJU Int. 2015 Jul 24. doi: 10.1111/bju.13239.
    PubMed     Text format     Abstract available


  169. RUSSO F, Regge D, Armando E, Giannini V, et al
    Detection of prostate cancer index lesions with multiparametric MRI (mp-MRI) using whole-mount histological sections as the reference standard.
    BJU Int. 2015 Jul 20. doi: 10.1111/bju.13234.
    PubMed     Text format     Abstract available


  170. LEE RJ, Tzou KS, Heckman MG, Hobbs CJ, et al
    Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy.
    BJU Int. 2015 Jul 18. doi: 10.1111/bju.13229.
    PubMed     Text format     Abstract available


  171. BOLTON D, Papa N, Ta A, Millar J, et al
    Predictors of Prostate Cancer Specific Mortality after Radical Prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry.
    BJU Int. 2015 Jul 14. doi: 10.1111/bju.13112.
    PubMed     Text format     Abstract available


  172. PRABHU V, Lee T, Loeb S, Holmes JH, et al
    Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigen.
    BJU Int. 2015;116:65-71.
    PubMed     Text format     Abstract available


  173. EMINAGA O, Hinkelammert R, Abbas M, Titze U, et al
    Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies.
    BJU Int. 2015;116:57-64.
    PubMed     Text format     Abstract available


    June 2015
  174. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Text format     Abstract available


  175. SCHMID M, Sammon JD, Reznor G, Kapoor V, et al
    The dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
    BJU Int. 2015 Jun 13. doi: 10.1111/bju.13203.
    PubMed     Text format     Abstract available


  176. DAOUACHER G, von Below C, Gestblom C, Ahlstrom H, et al
    Laparoscopic extended pelvic lymph node dissection as validation of the performance of [ C]-acetate-PET/CT in detection of lymph node metastasis in intermediate and high-risk prostate cancer.
    BJU Int. 2015 Jun 13. doi: 10.1111/bju.13202.
    PubMed     Text format     Abstract available


  177. DAVIS JW, Ward JF 3rd, Pettaway CA, Wang X, et al
    Disease reclassification risk with stringent criteria and frequent monitoring in men with favorable-risk prostate cancer undergoing active surveillance.
    BJU Int. 2015 Jun 8. doi: 10.1111/bju.13193.
    PubMed     Text format     Abstract available


  178. HEIDENREICH A
    Choline-positron emission tomography/CT in patients with relapsing prostate cancer: to be performed with therapeutic consequences only.
    BJU Int. 2015;115:849-50.
    PubMed     Text format    


  179. KLAFF R, Berglund A, Varenhorst E, Hedlund PO, et al
    Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases.
    BJU Int. 2015 Jun 1. doi: 10.1111/bju.13190.
    PubMed     Text format     Abstract available


  180. SENGUPTA S, Grimison P, Hayne D, Williams S, et al
    The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group--a new co-operative cancer trials group in genitourinary oncology.
    BJU Int. 2015;115:856-8.
    PubMed     Text format    


  181. JINDAL T, Mukherjee S, Sinha RK, Kamal MR, et al
    Transrectal ultrasonography (TRUS)-guided pelvic plexus block to reduce pain during prostate biopsy: a randomised controlled trial.
    BJU Int. 2015;115:892-6.
    PubMed     Text format     Abstract available


  182. FOSSATI N, Lazzeri M, Haese A, McNicholas T, et al
    Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
    BJU Int. 2015;115:913-20.
    PubMed     Text format     Abstract available


  183. PAL RP, Kockelbergh RC, Pringle JH, Cresswell L, et al
    Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.
    BJU Int. 2015 Jun 1. doi: 10.1111/bju.13184.
    PubMed     Text format     Abstract available


    May 2015
  184. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Text format     Abstract available


  185. LAIRD A, Fowler S, Good DW, Stewart GD, et al
    Contemporary practice and technique-related outcomes for radical prostatectomy in the UK: a report of national outcomes.
    BJU Int. 2015;115:753-63.
    PubMed     Text format     Abstract available


  186. HONG CW, Rais-Bahrami S, Walton-Diaz A, Shakir N, et al
    Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsies obtained from axial and sagittal approaches.
    BJU Int. 2015;115:772-9.
    PubMed     Text format     Abstract available


  187. GREY AD, Chana MS, Popert R, Wolfe K, et al
    Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.
    BJU Int. 2015;115:728-35.
    PubMed     Text format     Abstract available


  188. CAFFO O, De Giorgi U, Fratino L, Lo Re G, et al
    Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
    BJU Int. 2015;115:764-71.
    PubMed     Text format     Abstract available


  189. VOLANIS D, Neal DE, Warren AY, Gnanapragasam VJ, et al
    Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature.
    BJU Int. 2015;115:698-704.
    PubMed     Text format     Abstract available


    April 2015
  190. SCHMID M, Meyer CP, Trinh QD
    The need for standardised reporting of complications. Re: Minimum 5-years follow-up of 1138 consecutive laparoscopic radical prostatectomies.
    BJU Int. 2015;115:501-2.
    PubMed     Text format    


  191. KASTNER C
    A urologists' guide to the multi-parametric magnetic resonance imaging (mpMRI)-galaxy.
    BJU Int. 2015;115:503-4.
    PubMed     Text format    


  192. LOEB S
    Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
    BJU Int. 2015;115:500.
    PubMed     Text format    


  193. SALAMI SS, Ben-Levi E, Yaskiv O, Ryniker L, et al
    In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
    BJU Int. 2015;115:562-70.
    PubMed     Text format     Abstract available


  194. SOARES R, Di Benedetto A, Dovey Z, Bott S, et al
    Minimum 5-year follow-up of 1138 consecutive laparoscopic radical prostatectomies.
    BJU Int. 2015;115:546-53.
    PubMed     Text format     Abstract available


  195. BROUSIL P, Hussain M, Lynch M, Laing RW, et al
    Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    BJU Int. 2015;115:580-6.
    PubMed     Text format     Abstract available


    March 2015
  196. MOSCA A
    Enzalutamide withdrawal syndrome: is there a rationale?
    BJU Int. 2015;115:348-9.
    PubMed     Text format    


  197. RODRIGUEZ-VIDA A, Bianchini D, Van Hemelrijck M, Hughes S, et al
    Is there an antiandrogen withdrawal syndrome with enzalutamide?
    BJU Int. 2015;115:373-80.
    PubMed     Text format     Abstract available


  198. TAKESHITA H, Kawakami S, Numao N, Sakura M, et al
    Diagnostic performance and safety of a three-dimensional 14-core systematic biopsy method.
    BJU Int. 2015;115:412-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: